Gyomor- és nyelőcsőrák: vizsgálatok itt: Brazília
22 trials · From ClinicalTrials.gov, checked 2026. november 13.. Ask the study team whether a trial fits you.
- 1/2. fázisTaking peopleA Clinical Trial of Ifinatamab Deruxtecan in People With Advanced Esophageal Cancer (MK-3475-06F)
- Where
- Natal, Porto Alegre
- Életkor
- 18 év and over
- People
- 60 worldwide
- Run by
- Merck Sharp & Dohme LLC
See details and how to joinNCT07405151 · EU 2026-525213-31-00 - 3. fázisTaking peopleA Study of Zolbetuximab Together With Pembrolizumab and Chemotherapy in Adults With Gastric Cancer
- Where
- Belo Horizonte, Blumenau, Fortaleza, Jaú, Lages, Porto Alegre, São Caetano do Sul, São José do Rio Preto, São Paulo
- Életkor
- 18 év and over
- People
- 500 worldwide
- Run by
- Astellas Pharma Global Development, Inc.
See details and how to joinNCT06901531 · EU 2024-519773-19-00 - 2/3. fázisTaking peopleA Study to Evaluate the Safety and Efficacy of Pumitamig in Combination With Chemotherapy Versus Nivolumab in Combination With Chemotherapy in Participants With Previously Untreated Advanced or Metastatic Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma (ROSETTA Gastric-204)
- Where
- Belo Horizonte, Fortaleza, Natal, Porto Alegre, Santa Maria, São José do Rio Preto
- Életkor
- 18 év and over
- People
- 690 worldwide
- Run by
- Bristol-Myers Squibb
See details and how to joinNCT07221149 · EU 2025-523263-37-00 - 1/2. fázisTaking peopleSubstudy 06E: Umbrella Study of Combination Therapies in Esophageal Cancer (MK-3475-06E/KEYMAKER-U06)
- Where
- Natal, Porto Alegre, São Paulo
- Életkor
- 18 év and over
- People
- 298 worldwide
- Run by
- Merck Sharp & Dohme LLC
See details and how to joinNCT06780111 · EU 2024-514273-22-00 - 1/2. fázisTaking peopleA Study to Evaluate the Efficacy and Safety of Ifinatamab Deruxtecan (I-DXd) in Subjects With Recurrent or Metastatic Solid Tumors (IDeate-PanTumor02)
- Where
- Barretos, Florianópolis, Jaú, Porto Alegre
- Életkor
- 18 év and over
- People
- 680 worldwide
- Run by
- Daiichi Sankyo
See details and how to joinNCT06330064 · EU 2023-509632-26-00 - 3. fázisTaking peopleA Phase Ⅲ Study of Rilvegostomig in Combination With Fluoropyrimidine and Trastuzumab Deruxtecan as the First-line Treatment for HER2-positive Gastric Cancer
- Where
- Barretos, Brasília, Campo Grande, Natal, Porto Alegre, Recife, Salvador, São Paulo, Vitória
- Életkor
- 18 év and over
- People
- 840 worldwide
- Run by
- AstraZeneca
See details and how to joinNCT06764875 · EU 2024-512583-57-00 - 3. fázisTaking peopleSonesitatug Vedotin in Combination With Capecitabine With or Without Rilvegostomig in Participants With Advanced or Metastatic Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma Expressing Claudin18.2
- Where
- Barretos, Fortaleza, Natal, Porto Alegre, Salvador, Santa Maria, São Paulo, Vitória
- Életkor
- 18 év and over
- People
- 2130 worldwide
- Run by
- AstraZeneca
See details and how to joinNCT07431281 · EU 2024-519787-40-00 - 3. fázisTaking peopleA Study to Investigate Tislelizumab Administered as Subcutaneous Injection Versus Intravenous Infusion Plus Chemotherapy in Patients With Unresectable or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma
- Where
- Barretos, Blumenau, Brasília, Natal, Porto Alegre, Recife, Rio de Janeiro, São José do Rio Preto, São Paulo, Vitória
- Életkor
- 18 év and over
- People
- 351 worldwide
- Run by
- BeOne Medicines
See details and how to joinNCT07043400 · EU 2025-522862-58-00 - 1/2. fázisTaking peopleA Study to Evaluate Investigational Agents With or Without Pembrolizumab (MK-3475) in Participants With Advanced Esophageal Cancer Previously Exposed to Programmed Cell Death 1 Protein (PD-1)/ Programmed Cell Death Ligand 1 (PD-L1) Treatment (MK-3475-06B)
- Where
- Natal, Porto Alegre, São Paulo
- Életkor
- 18 év and over
- People
- 230 worldwide
- Run by
- Merck Sharp & Dohme LLC
See details and how to joinNCT05319730 · EU 2023-505189-26-00 - 1/2. fázisTaking peopleSubstudy 06C: A Study of Investigational Agents With Pembrolizumab (MK-3475) and Chemotherapy in Participants With First-Line Locally Advanced Unresectable/Metastatic Gastroesophageal Adenocarcinoma (MK-3475-06C/KEYMAKER-U06)
- Where
- Natal, Porto Alegre, São Paulo
- Életkor
- 18 év and over
- People
- 160 worldwide
- Run by
- Merck Sharp & Dohme LLC
See details and how to joinNCT06469944 · EU 2023-509307-33-00 - 1/2. fázisTaking peopleA Phase 1/2 Study of BGB-B2033, Alone or in Combination With Tislelizumab With or Without Bevacizumab, in Participants With Advanced or Metastatic Solid Tumors
- Where
- Barretos, Porto Alegre, Salvador, São José do Rio Preto, São Paulo
- Életkor
- 18 év and over
- People
- 630 worldwide
- Run by
- BeOne Medicines
See details and how to joinNCT06427941 · EU 2025-524136-19-00 - 2. fázisTaking peopleStudy of Volrustomig as Monotherapy or in Combination With Anti- Cancer Agents in Participants With Advanced/Metastatic Solid Tumors
- Where
- Ijuí, Londrina, Natal, Porto Alegre, Santo André, São Caetano do Sul, Vitória
- Életkor
- 18 év to 64 év
- People
- 257 worldwide
- Run by
- AstraZeneca
See details and how to joinNCT06535607 · EU 2025-523947-36-00 - 1/2. fázisTaking peopleSubstudy 06D: Combination Therapies in Second Line (2L) Gastroesophageal Adenocarcinoma (MK-3475-06D/Keymaker-U06)
- Where
- Natal, Porto Alegre, São Paulo
- Életkor
- 18 év and over
- People
- 210 worldwide
- Run by
- Merck Sharp & Dohme LLC
See details and how to joinNCT06445972 · EU 2023-509306-29-00 - 3. fázisTaking peopleStudy of TDXd, Chemotherapy, Pembrolizumab, and Trastuzumab in First-Line Metastatic HER2-Positive Gastric or Gastroesophageal Junction Cancer
- Where
- Brasília, Brazil, Florianópolis, Jaú, Natal, Porto Alegre, Recife, Ribeirão Preto, Rio de Janeiro, Salvador, Sao Jose Rio Preto
- Életkor
- 18 év and over
- People
- 726 worldwide
- Run by
- Daiichi Sankyo
See details and how to joinNCT06731478 - No phaseTaking peopleComparative Study Between (FC-SEMS) and (PC-SEMS) in the Palliation of Dysphagia Due to Malignant Neoplasm of Esophagus.
- Where
- São Paulo
- Életkor
- 18 év and over
- People
- 34
- Run by
- Instituto do Cancer do Estado de São Paulo
See details and how to joinNCT06070376 - No phaseTaking peopleComparison of 0.4% Hyaluronic Acid Solution Versus Hydroxyethylamide Solution in Submucosal Endoscopic Resections
- Where
- São Paulo
- Életkor
- 18 év and over
- People
- 30
- Run by
- Instituto do Cancer do Estado de São Paulo
See details and how to joinNCT06077981 - 2. fázisTaking peopleEffectiveness and Performance of an Optical Biopsy Technology for Esophageal Cancer in Brazil and the United States
- Where
- Barretos, São Paulo
- Életkor
- 18 év and over
- People
- 200 worldwide
- Run by
- Baylor College of Medicine
See details and how to joinNCT06435286 - 3. fázisTaking peopleA Phase Ⅲ Clinical Study of HLX22 in Combination With Trastuzumab and Chemotherapy for the Treatment of Gastroesophageal Junction and Gastric Cancer
- Where
- Belo Horizonte, Curitiba, Lages, Porto Alegre, Recife, Santa Maria, São Paulo, Vila Mariana
- Életkor
- 18 év and over
- People
- 550 worldwide
- Run by
- Shanghai Henlius Biotech
See details and how to joinNCT06532006 · EU 2024-516633-12-00 - No phaseNot yet taking people in BrazíliaProteomic Analysis of Patients Undergoing Bariatric Surgery
- Where
- Recife
- Életkor
- 18 év and over
- People
- 103
- Run by
- Universidade Federal de Pernambuco
See details and how to joinNCT06787807 - No phaseTaking peopleDistribution of Lymph Node Metastases in Esophageal Carcinoma
- Where
- Rio de Janeiro
- Életkor
- 18 év and over
- People
- 5000 worldwide
- Run by
- Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)
See details and how to joinNCT03222895 - No phaseTaking peopleScreening of Gastric Cancer Via Breath Volatile Organic Compounds by Hybrid Sensing Approach
- Where
- São Paulo
- Életkor
- 18 év and over
- People
- 5000 worldwide
- Run by
- University of Latvia
See details and how to joinNCT04022109 - 2. fázisTaking peopleNeoadjuvant FOLFIRINOX in the Treatment of Locally Advanced Gastric Cancer
- Where
- São Paulo
- Életkor
- 18 év to 75 év
- People
- 27
- Run by
- Instituto do Cancer do Estado de São Paulo
See details and how to joinNCT03825861